Related Experiment Videos
[Organ transplantation: development, possibilities, socioeconomic aspects]
Versicherungsmedizin
|January 1, 1989
Summary
Cyclosporin A has significantly improved organ transplant survival rates, expanding treatment options for kidney, pancreas, liver, and heart patients. Success evaluation requires considering transplant factors and patient health, particularly from the second year post-transplant.
Area of Science:
- Immunology
- Transplantation Surgery
- Pharmacology
Context:
- Clinical organ transplantation has seen dramatic advancements.
- The introduction of Cyclosporin A, a potent immunosuppressant, has revolutionized transplant outcomes.
- Surgical techniques for kidney, liver, and heart transplantation are established, while pancreatic transplantation techniques are still evolving.
Purpose:
- To highlight the impact of Cyclosporin A on organ transplantation.
- To discuss the improved graft survival rates and expanded indications for transplantation.
- To outline considerations for medical insurance evaluation of transplant procedures.
Summary:
- Cyclosporin A has drastically improved 1-year graft survival rates in kidney, pancreas, liver, and heart transplantation.
- This has led to a significant widening of indications for various organ transplant procedures.
- Surgical techniques are largely resolved for kidney, liver, and heart transplants, but pancreatic transplantation requires further development.
- Medical insurance evaluation should currently focus on successful kidney transplant recipients, assessing success from the second year post-transplant.
- High-risk factors for insurance considerations include transplant-related issues (e.g., HLA-matching) and patient-specific factors (e.g., age, comorbidities).
Impact:
- Improved patient outcomes and increased availability of life-saving organ transplants.
- Enhanced understanding of immunosuppression's role in transplant success.
- Foundation for future research in transplantation and immunosuppressive therapies.